The applications of biosimulation include obtaining a quantitative understanding of regulation of blood levels and glucose simulated insulin secretion in order to investigate the role the various physiological processes play in diabetes and others. The areas of future research in biosimulation include obtaining a better understanding of disease heterogeneity and the biological changes that occur during disease progression to predict the effects of various therapeutic approaches on different categories of people.
The report segments the global Bio Simulation market by product, application, end user, and region. The products include drug discovery, drug development, and others (defense, industrial bioprocessing, nutraceuticals, and agri-food production).
The drug development application segment is further classified into preclinical testing and clinical trials. The drug discovery segment is divided into target identification & validation and lead identification & optimization. The end users for this market are academic and government research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, and other end users (defense, nutraceuticals companies, and food and agricultural companies).
Geographic Coverage and Analysis:
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. North America dominated the global bio simulation market and holds more than half of the share value as compared to total global sale. This growth in North America is significantly driven by off patenting of many drugs and search for new drug moiety. Europe stands next to North America for global bio simulation market where growth is majorly driven by government initiatives. Asia-pacific is emerging market where the growth is driven by increase in number of CRO’s.
The companies covered in the report include Certara USA, Inc. (U.S.), Simulation Plus Inc. (U.S.), Dassault Systèmes SA (France), Schrödinger Inc. (U.S.), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group, Inc. (Canada), Physiomics PLC (U.K.), Entelos Holding Corporation (U.S.), Rhenovia Pharma Ltd. (France), and Genedata AG (Switzerland).
The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of Bio Simulation globally as well as regionally. Moreover, the Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter’s five forces analysis and value chain analysis of Bio Simulation.
Moreover, the study highlights current market trends and provides forecast from 2016 to 2021. We also have highlighted future trends in the Bio Simulation market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. Additionally, the analysis highlights rise and fall in the market shares of the key players in the market. This report will help manufacturers, suppliers and distributors of the Bio Simulation market to understand the present and future trends in this market and formulate their strategies accordingly.
1.1 Report Description
1.2 Research Methods
1.3 Research Approaches
2. Executive Summary
3. Global Bio Simulation Market Overview
3.2 Market Dynamics
3.3 Porter’s Five Forces Analysis
3.4 Author - Growth Matrix Analysis
3.5 Competitive Landscape in the Bio Simulation Market
4. Global Bio Simulation Market Analysis, by Product (USD Million, KT) 2014-2021
4.1.1 PK/PD Modeling and Simulation Software
4.1.2 Molecular Modeling and Simulation Software
4.1.3 Pbpk Modeling and Simulation Software
4.1.4 Toxicity Prediction Software
4.1.5 Trial Design Software
4.1.6 Other Software
4.2.1 In-House Services
4.2.2 External/Contract Services
5. Global Bio Simulation Market Analysis, by Application (USD Million, KT) 2014-2021
5.1 Drug Development
5.1.1 Preclinical Testing
5.1.2 Clinical Trials
5.2 Drug Discovery
5.2.1 Target Identification and Validation
5.2.2 Lead Identification and Optimization
5.3 Other Applications
6. Global Bio Simulation Market Analysis, by End User (USD Million, KT) 2014-2021
6.1 Pharmaceutical and Biotechnology Companies
6.2 Academic and Government Research Institutes
6.3 Contract Research Organizations
6.4 Regulatory Authorities
6.5 Other End Users
7. Global Bio Simulation Market Analysis, by Region (USD Million, KT) 2014-2021
7.1 North America
7.1.1 North America Bio Simulation Market by Product (USD Million, KT)
7.1.2 North America Bio Simulation Market by Application (USD Million, KT)
7.1.3 North America Bio Simulation Market by End User (USD Million, KT)
7.2.1 Europe Bio Simulation Market by Product (USD Million, KT)
7.2.2 Europe Bio Simulation Market by Application (USD Million, KT)
7.2.3 Europe Bio Simulation Market by End User (USD Million, KT)
7.3.1 Asia-Pacific Bio Simulation Market by Product (USD Million, KT)
7.3.2 Asia-Pacific Bio Simulation Market by Application (USD Million, KT)
7.3.3 Asia-Pacific Bio Simulation Market by End User (USD Million, KT)
7.4 Rest of the World (RoW)
7.4.1 RoW Bio Simulation Market by Product (USD Million, KT)
7.4.2 RoW Bio Simulation Market by Application (USD Million, KT)
7.4.3 RoW Bio Simulation Market by End User (USD Million, KT)
8. Company Profiles
8.1 Certara USA, Inc.
8.2 Simulation Plus Inc.
8.3 Dassault Systèmes SA
8.4 Schrödinger Inc.
8.5 Advanced Chemistry Development, Inc.
8.6 Chemical Computing Group, Inc.
8.7 Entelos Holding Corporation
8.8 Genedata Ag
8.9 Physiomics PLC
8.10 Rhenovia Pharma Ltd.
- Certara USA, Inc.
- Chemical Computing Group, Inc.
- Dassault Systèmes SA
- Entelos Holding Corporation
- Genedata Ag
- Physiomics PLC
- Rhenovia Pharma Ltd.
- Schrödinger Inc.
- Simulation Plus Inc.